跳至主要内容
临床试验/NCT03953053
NCT03953053已完成不适用

Safety and Efficacy of FLACS With the FEMTO LDV Z8 Laser Compared to Conventional Cataract Surgery in Chinese Patients

Ziemer Ophthalmic Systems AG1 个研究点 分布在 1 个国家目标入组 132 人开始时间: 2019年6月3日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
132
试验地点
1
主要终点
Endothelial cell loss

研究概览

简要总结

This trial will be designed as a multi-center randomized non-inferiority clinical trial to demonstrate safety and efficacy of the FEMTO LDV Z8 laser for cataract surgery in a Chinese population in China compared to the conventional technique.

详细描述

In this three center, prospective, interventional, randomized controlled study we aim to determine safety and efficacy of the FEMTO LDV Z8 laser as compared to conventional technique in Chinese patients diagnosed with cataract of any severity grade that are eligible to undergo cataract surgery with age 50 years and a maximum age of 80 years in China.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
50 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Eligible to undergo cataract extraction by phacoemulsification with primary intraocular lens implantation
  • Provision of signed and dated informed consent form
  • Male or female, between 50 and 80 years of age (50 and 80 are included).
  • IOL chosen for implantation a monofocal aspheric IOL of 6mm optic diameter
  • Willing to comply with all study procedures and able to return for scheduled follow-up examinations
  • Willing to adhere to the medication (to prevent inflammation and infection) regimen

排除标准

  • Corneal disease or pathology, such as corneal scaring or opacity, that precludes transmission of laser wavelength or that distorts laser light
  • Poorly dilating pupil or other defect of the pupil that prevents the iris from adequate retraction peripherally (e.g., intraoperative floppy iris syndrome)
  • Glaucoma or ocular hypertension, pseudoexfoliation
  • Corneal endothelial pathology where endothelial cell count is compromised (Fuchs endothelial dystrophy and others)
  • Complicated cataract, such as traumatic, white, intumescent or posterior and anterior subcapsular cataracts
  • Nystagmus or hemofacial spasm preventing placement of the patient interface
  • Previous intraocular or corneal surgery of any kind, including any type of surgery for either refractive or therapeutic purposes in either eye
  • Allergy to medications required in surgery, pre- and post-operative treatment
  • History of lens or zonular instability
  • Keratoconus or keratectasia
  • Immune compromised or diagnosis of ophthalmic disease: ocular herpes zoster or simplex, lupus, collagenosis and other acute or chronic illnesses that increases the risk to the subject or confounds the outcomes of this study in the opinion of the study PI (Principal Investigator)
  • Anterior chamber depth (ACD) < 1.5 mm or > 4.8 mm as measured from the corneal endothelium.
  • Developmental disability or cognitive impairment that would make informed consent and the assessment of visual acuity impossible
  • Concurrent participation in another ophthalmological clinical study

结局指标

主要结局

Endothelial cell loss

时间窗: 4 month

To determine whether the FLACS with the FEMTO LDV Z8 laser is non-inferior to measured using the NSP 9900, KONAN MEDICAL, and calculated according to: postoperative endothelial cell loss = preoperative endothelial count - postoperative endothelial cell count

次要结局

  • Corneal thickness (CCT)(4 month)
  • Intra- and post- surgical complications(4 month)
  • Cumulative dissipated energy (CDE)(4 month)
  • Uncorrected distance visual acuity (UDVA)(4 month)
  • Ultrasound (US) total time(4 month)
  • Estimated fluid usage (EFU)(4 month)
  • Corrected distance visual acuity (CDVA)(4 month)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验